Bavarian Nordic Receives $1.6-Billion Contract from HHS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bavarian Nordic Receives $1.6-Billion Contract from HHS


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Kvistgård, Denmark (June 4)—Bavarian Nordic received a $1.6-billion contract from the US Department of Health and Human Services (HHS, Washington, DC) to manufacture and deliver 20 million doses of its smallpox vaccine “Imvamune.”

HHS is supplying a base contract payment of $500 million to support additional research and development of Imvamune for the vaccine’s potential use during an emergency. The payment also will fund nonclinical and clinical studies for the vaccine.

The contract includes advance and milestone payments worth as much as $150 million and contractual options worth $1.1 billion. The contractual-options payment would fund further clinical studies of the vaccine that extend the license to include those infected with HIV, children, and the elderly. The payment also could be used to procure up to 60 million additional doses of Imvamune.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here